Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Melanocytes | 3 | 2021 | 515 | 0.580 |
Why?
|
Melanoma | 6 | 2021 | 5510 | 0.520 |
Why?
|
Drug Eruptions | 1 | 2015 | 297 | 0.430 |
Why?
|
Ultraviolet Rays | 3 | 2021 | 1060 | 0.300 |
Why?
|
Skin Pigmentation | 2 | 2021 | 282 | 0.260 |
Why?
|
Molecular Targeted Therapy | 2 | 2019 | 2727 | 0.240 |
Why?
|
Interferon Regulatory Factor-1 | 1 | 2021 | 68 | 0.200 |
Why?
|
SOXE Transcription Factors | 1 | 2021 | 57 | 0.200 |
Why?
|
Skin Diseases, Viral | 1 | 2021 | 21 | 0.200 |
Why?
|
Endorphins | 1 | 2021 | 75 | 0.200 |
Why?
|
Purpura | 1 | 2021 | 122 | 0.180 |
Why?
|
Interferon Regulatory Factors | 1 | 2021 | 270 | 0.180 |
Why?
|
Pressure Ulcer | 1 | 2021 | 155 | 0.180 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2021 | 252 | 0.170 |
Why?
|
Histocompatibility Antigens | 1 | 2020 | 471 | 0.170 |
Why?
|
Receptors, CXCR3 | 1 | 2019 | 237 | 0.160 |
Why?
|
Neuroglia | 1 | 2023 | 927 | 0.150 |
Why?
|
Melanoma, Experimental | 2 | 2020 | 561 | 0.150 |
Why?
|
Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2017 | 51 | 0.150 |
Why?
|
Tumor Escape | 2 | 2017 | 349 | 0.150 |
Why?
|
Exanthema | 1 | 2021 | 501 | 0.140 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2021 | 789 | 0.140 |
Why?
|
Skin Diseases, Papulosquamous | 1 | 2015 | 18 | 0.140 |
Why?
|
Protein Biosynthesis | 1 | 2023 | 2126 | 0.130 |
Why?
|
Hypopigmentation | 1 | 2015 | 41 | 0.130 |
Why?
|
Histone-Lysine N-Methyltransferase | 1 | 2020 | 670 | 0.130 |
Why?
|
Immunomodulation | 1 | 2019 | 541 | 0.130 |
Why?
|
Skin Neoplasms | 1 | 2014 | 5686 | 0.130 |
Why?
|
Antigens, Neoplasm | 2 | 2021 | 1988 | 0.130 |
Why?
|
Reverse Transcription | 1 | 2014 | 47 | 0.120 |
Why?
|
Chromosome Mapping | 1 | 2023 | 4740 | 0.120 |
Why?
|
Moloney murine leukemia virus | 1 | 2014 | 139 | 0.120 |
Why?
|
Nucleocapsid Proteins | 1 | 2014 | 77 | 0.120 |
Why?
|
Dermatology | 2 | 2022 | 872 | 0.120 |
Why?
|
Epitopes | 1 | 2021 | 2571 | 0.120 |
Why?
|
Oncogenes | 1 | 2020 | 1265 | 0.120 |
Why?
|
Neoplasms | 3 | 2019 | 21683 | 0.120 |
Why?
|
RNA, Messenger | 3 | 2023 | 13033 | 0.110 |
Why?
|
Sunlight | 1 | 2014 | 325 | 0.110 |
Why?
|
RNA | 1 | 2023 | 2749 | 0.110 |
Why?
|
Immunotherapy | 3 | 2021 | 4445 | 0.110 |
Why?
|
Pruritus | 1 | 2015 | 361 | 0.110 |
Why?
|
Antineoplastic Agents | 1 | 2015 | 13695 | 0.110 |
Why?
|
Forkhead Transcription Factors | 1 | 2020 | 1613 | 0.110 |
Why?
|
Hair Color | 1 | 2012 | 136 | 0.100 |
Why?
|
RNA, Transfer | 1 | 2014 | 316 | 0.100 |
Why?
|
Vitamin D Deficiency | 1 | 2021 | 1343 | 0.100 |
Why?
|
Skin Diseases | 1 | 2019 | 1065 | 0.090 |
Why?
|
Proto-Oncogene Proteins B-raf | 3 | 2020 | 2043 | 0.090 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2014 | 547 | 0.090 |
Why?
|
Referral and Consultation | 2 | 2022 | 3528 | 0.090 |
Why?
|
Mice | 9 | 2023 | 81183 | 0.080 |
Why?
|
Drug Approval | 1 | 2014 | 742 | 0.080 |
Why?
|
Monophenol Monooxygenase | 2 | 2021 | 69 | 0.080 |
Why?
|
Length of Stay | 1 | 2021 | 6309 | 0.080 |
Why?
|
Drug Administration Schedule | 1 | 2015 | 4933 | 0.080 |
Why?
|
Opioid-Related Disorders | 1 | 2021 | 2065 | 0.070 |
Why?
|
RNA, Viral | 1 | 2014 | 2902 | 0.070 |
Why?
|
Epigenesis, Genetic | 2 | 2019 | 3647 | 0.070 |
Why?
|
Animals | 11 | 2023 | 168757 | 0.070 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2019 | 3557 | 0.060 |
Why?
|
Telemedicine | 1 | 2022 | 2872 | 0.060 |
Why?
|
Models, Molecular | 1 | 2014 | 5456 | 0.060 |
Why?
|
Neurons | 1 | 2023 | 9338 | 0.060 |
Why?
|
Mice, Inbred C57BL | 5 | 2021 | 21827 | 0.060 |
Why?
|
Humans | 18 | 2023 | 744343 | 0.050 |
Why?
|
Melanosomes | 1 | 2021 | 31 | 0.050 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2020 | 1038 | 0.050 |
Why?
|
Cell Line, Tumor | 4 | 2020 | 16689 | 0.050 |
Why?
|
Prone Position | 1 | 2021 | 194 | 0.040 |
Why?
|
Tumor Cells, Cultured | 2 | 2021 | 6314 | 0.040 |
Why?
|
Clinical Trials as Topic | 1 | 2015 | 7913 | 0.040 |
Why?
|
Hospitals, Urban | 1 | 2021 | 499 | 0.040 |
Why?
|
Disease Progression | 1 | 2015 | 13284 | 0.040 |
Why?
|
Gene Expression Regulation | 3 | 2023 | 12072 | 0.040 |
Why?
|
Cyclic AMP | 1 | 2021 | 1472 | 0.040 |
Why?
|
HeLa Cells | 1 | 2023 | 3128 | 0.040 |
Why?
|
Brain | 1 | 2023 | 26385 | 0.030 |
Why?
|
Ubiquitin | 1 | 2021 | 852 | 0.030 |
Why?
|
Oxidation-Reduction | 1 | 2021 | 2187 | 0.030 |
Why?
|
Unfolded Protein Response | 1 | 2017 | 233 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2020 | 1878 | 0.030 |
Why?
|
Kinetics | 1 | 2023 | 6473 | 0.030 |
Why?
|
Indoles | 2 | 2014 | 1839 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2021 | 1338 | 0.030 |
Why?
|
Retrospective Studies | 3 | 2021 | 77449 | 0.030 |
Why?
|
Mutation | 2 | 2020 | 29786 | 0.030 |
Why?
|
Immunocompetence | 1 | 2014 | 137 | 0.030 |
Why?
|
Cell Line | 2 | 2021 | 15997 | 0.030 |
Why?
|
Sulfonamides | 2 | 2014 | 1938 | 0.030 |
Why?
|
Interferons | 1 | 2017 | 706 | 0.030 |
Why?
|
Survival Analysis | 2 | 2020 | 10252 | 0.030 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 11524 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2019 | 4479 | 0.030 |
Why?
|
Intubation, Intratracheal | 1 | 2021 | 1364 | 0.030 |
Why?
|
Vitamins | 1 | 2021 | 1622 | 0.030 |
Why?
|
Receptor, Melanocortin, Type 1 | 1 | 2012 | 76 | 0.030 |
Why?
|
Single-Cell Analysis | 1 | 2023 | 2183 | 0.030 |
Why?
|
Peroxidases | 1 | 2012 | 138 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2021 | 10481 | 0.030 |
Why?
|
Lymphocyte Count | 1 | 2014 | 793 | 0.030 |
Why?
|
Nuclear Magnetic Resonance, Biomolecular | 1 | 2014 | 507 | 0.020 |
Why?
|
Antigen Presentation | 1 | 2017 | 1284 | 0.020 |
Why?
|
DNA Damage | 1 | 2021 | 2432 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6489 | 0.020 |
Why?
|
T-Lymphocytes | 2 | 2020 | 10180 | 0.020 |
Why?
|
T-Lymphocyte Subsets | 1 | 2019 | 1838 | 0.020 |
Why?
|
Hospitalization | 2 | 2021 | 10262 | 0.020 |
Why?
|
Genome, Viral | 1 | 2014 | 667 | 0.020 |
Why?
|
Melanins | 1 | 2012 | 289 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2021 | 2759 | 0.020 |
Why?
|
Enzyme Inhibitors | 1 | 2021 | 3798 | 0.020 |
Why?
|
Zebrafish | 1 | 2021 | 2994 | 0.020 |
Why?
|
Treatment Outcome | 1 | 2015 | 63114 | 0.020 |
Why?
|
NF-kappa B | 1 | 2017 | 2499 | 0.020 |
Why?
|
Mitochondria | 1 | 2021 | 3520 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2019 | 5524 | 0.020 |
Why?
|
Hospitals | 1 | 2022 | 3952 | 0.020 |
Why?
|
Medical Oncology | 1 | 2019 | 2265 | 0.020 |
Why?
|
Vitamin D | 1 | 2021 | 3223 | 0.020 |
Why?
|
Survival Rate | 1 | 2021 | 12788 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2014 | 3846 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2019 | 3586 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2023 | 9438 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2021 | 8428 | 0.020 |
Why?
|
Apoptosis | 1 | 2021 | 9727 | 0.020 |
Why?
|
Analgesics, Opioid | 1 | 2021 | 3674 | 0.020 |
Why?
|
Middle Aged | 4 | 2021 | 213383 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2019 | 14557 | 0.010 |
Why?
|
Aged | 3 | 2021 | 163280 | 0.010 |
Why?
|
Incidence | 1 | 2021 | 20947 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7279 | 0.010 |
Why?
|
Protein Binding | 1 | 2014 | 9386 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2021 | 15519 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10943 | 0.010 |
Why?
|
Pandemics | 1 | 2022 | 8388 | 0.010 |
Why?
|
Genomics | 1 | 2017 | 5720 | 0.010 |
Why?
|
Prognosis | 1 | 2021 | 29063 | 0.010 |
Why?
|
Male | 4 | 2021 | 350118 | 0.010 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2014 | 2988 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18029 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2021 | 17446 | 0.010 |
Why?
|
Cytokines | 1 | 2014 | 7322 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 40561 | 0.010 |
Why?
|
Female | 3 | 2021 | 380194 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2014 | 9274 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2012 | 5535 | 0.010 |
Why?
|
Adult | 2 | 2021 | 214055 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2020 | 57776 | 0.010 |
Why?
|
Concepts
(149)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(53)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_